摘要
目的：观察瑞舒伐他汀与阿托伐他汀治疗冠心病随机对照研究。方法选择2013年4月～2013年9月我院收治的冠心病患者160例为临床研究对象，随机分为瑞舒伐他汀组和阿托伐他汀组两组，每组80例。连续治疗八周后观察两组疗效。结果两组患者的TG、LDL-C、TC、高敏C反应蛋白水平都比治疗前降低，HDL-C水平较治疗前升高，但瑞舒伐他汀组更为显著，P〈0.05，具有统计学意义。瑞舒伐他汀组治疗总有效率跟阿托伐他汀组相比，P〉0.05，没有统计学意义。结论瑞舒伐他汀与阿托伐他汀治疗冠心病均有一定效果，但瑞舒伐他汀在改善患者血脂等实验室指标方面效果更显著。
Objective To evaluate the clinical efficacy of rosuvastatin and atorvastatin in the treatment of coronary heart disease. Methods In April 2013 to September 2013,160 cases of coronary heart disease patients of our hospital for clinical research object,were randomly divided into rosuvastatin group and atorvastatin group,80 cases in each group. For eight weeks after treatment to observe curative effect of the two groups. Results Two groups of patients with TG,LDL-C,TC,high-sensitivity c-reactive protein levels were significantly lower than before treatment,the level of HDL-C than before treatment significantly increased,but rosuvastatin group was more significant,P〈0.05,with statistical significance. These was no statistical significance in two group for total effectiveness,P〉0.05. Conclusion rosuvastatin with atorvastatin therapy of coronary heart disease have a certain effect,but rosuvastat has a more significant effect of in improving patients＇ blood lipids.
出处
《中国卫生标准管理》
2015年第11期47-48,共2页
China Health Standard Management
关键词
瑞舒伐他汀
阿托伐他汀
冠心病
Rosuvastatin
Atorvastatin
Coronary heart disease
